Esperion Therapeutics

Lipid-lowering therapeutics

Delisted (Nasdaq: ESPR): taken private by ARCHIMED, merger completed 2026-07-13 · United States

Assets

(2 total)
2Total Assets
2Approved
0Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Bempedoic acid(Nexletol)
Approved
ATP citrate lyaseSmall molecule
Atherosclerotic Cardiovascular Disease
Approved
ATP citrate lyase (ACLY, bempedoic acid) and NPC1L1 (ezetimibe)Small molecule
Atherosclerotic Cardiovascular Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Financial reports

Quarterly & interim (14)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1$80M$9.0M$156M$25Mreport ↗
View 13 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-Q3$87M$14M$92M$31Mreport ↗
2025-Q2$82M$7.2M$86M$13Mreport ↗
2025-Q1$65M$13M$115M$40Mreport ↗
2024-Q3$52M$10M$145M$30Mreport ↗
2024-Q2$74M$11M$189M$62Mreport ↗
2024-Q1$138M$13M$227M—report ↗
2023-Q3$34M$15M$115M$41Mreport ↗
2023-Q2$26M$22M$138M$50Mreport ↗
2023-Q1$24M$31M$145M$62Mreport ↗
2022-Q3$19M$29M$209M$55Mreport ↗
2022-Q2$19M$32M$173M$66Mreport ↗
2022-Q1$19M$24M$200M$57Mreport ↗
2021-Q3$14M$25M$154M$69Mreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$403M$48M$168M$5.7Mreport ↗

Esperion Therapeutics reported revenue of $403.14M, up 21.3% YoY, R&D spend of $47.85M, up 3.5% YoY, cash and equivalents of $167.85M, and a net loss of $22.68M for fiscal year 2025.

Figures only: this period's report disclosed no narrative text

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$332M$46M$145M$13Mreport ↗
2023-FY$116M$86M$82M$52Mreport ↗
2022-FY$75M$119M$125M$58Mreport ↗
2021-FY$78M$106M$259M$67Mreport ↗